Advanced Therapies Going Mainstream: Are We There Yet?

Advanced therapies are rapidly moving from niche to mainstream, with promising clinical trial results in cell therapies, oligonucleotides, and mRNA-based treatments. Scott Ripley, head of Cytiva’s Genomic Medicines Group, shares his perspective on how these modalities are evolving toward first-line treatments, highlighting recent approvals in oncology and emerging applications in autoimmune diseases. He also explores the next frontier for mRNA: personalized cancer vaccines, which could reshape treatment paradigms within the next decade. But with innovation comes the challenge of industrialization. Ripley outlines what manufacturers and suppliers must do to scale production, support new modalities, and enable flexible technologies. From ex vivo cell therapies to mRNA-LNPs for gene editing, the path forward requires collaboration, regulatory support, and manufacturing agility.

For those preparing for the next wave of biotherapeutics, explore insights that offer a clear-eyed look at what’s coming and what it will take to be ready.